**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 5339**

**Columns: REVIEW**

**Liver function impairment in liver transplantation and after extended hepatectomy**

Serenari M *et al*.Liver function impairment after hepatic surgery

Matteo Serenari, Matteo Cescon, Alessandro Cucchetti, Antonio Daniele Pinna

**Matteo Serenari, Matteo Cescon, Alessandro Cucchetti, Antonio Daniele Pinna,** General Surgery and Transplant Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy

**Author contributions:** Serenari M and Cucchetti A performed the literature search and wrote the paper; Cescon M provided critical expertise and reviewed the paper; Pinna AD helped with focusing the topics and provided critical expertise.

**Correspondence to:** **Alessandro Cucchetti, MD,** General Surgery and Transplant Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna Policlinico Sant'Orsola-Malpighi, Via Massarenti 9, 40138 Bologna, Italy. aleqko@libero.it

**Telephone:** +39-51-6363721  **Fax:** +39-51-304902

**Received:** August 30, 2013  **Revised:** Octomber 3, 2013

**Accepted:** Octomber 13, 2013

**Published online:**

**Abstract**

Extended hepatectomy, or liver transplantation of reduced-size graft, can lead to a pattern of clinical manifestations, namely “post-hepatectomy liver failure” and "small-for-size syndrome" respectively, that can range from mild cholestasis to irreversible organ non-function and death of the patient. Many mechanisms are involved in their occurrence but in the recent past, high portal blood flow through a relatively small liver vascular bed has taken a central role. Therefore, several techniques of inflow modulation have been attempted in cases of portal hyperperfusion first in liver transplantation, such as portocaval shunt, mesocaval shunt, splenorenal shunt, splenectomy or ligation of the splenic artery. However, high portal flow is not the only factor responsible, and before major liver resections, preoperative assessment of the residual liver function is necessary. Techniques such as portal vein embolization or portal vein ligation can be adopted to increase the future liver volume, preventing post-hepatectomy liver failure. More recently, a new surgical procedure, that combines *in situ* splitting of the liver and portal vein ligation, has gradually come to light, inducing remarkable hypertrophy of the healthy liver in just a few days. Further studies are needed to confirm this hypothesis and overcome one of the biggest issues in the field of liver surgery.

© 2013 Baishideng. All rights reserved.

**Key words:** Small-for-size syndrome; Liver transplantation; Extended hepatectomy; Liver failure; Cirrhosis

**Core tip:** In this review we focus on the small-for-size syndrome and post-hepatectomy liver failure, the most feared complications of liver surgery, fundamentally similar in pathogenesis and clinical manifestations, occurring when the residual liver is not large enough to accommodate the markedly increased portal vein blood ﬂow. Our aim is to simplify a concept, which has been a major concern in hepatic surgery for some time. Many efforts have been and are being made to overcome such an important problem in this field.

Serenari M, Cescon M, Cucchetti A, Pinna AD. Liver function impairment in liver transplantation and after extended hepatectomy. World J Gastroenterol 2013;

**Available from:** URL: http://www.wjgnet.com/1007-9327/

**DOI:** http://dx.doi.org/10.3748/wjg.

**INTRODUCTION**

The liver is a unique organ, capable of regeneration and functional recovery after parenchymal injury. When the volume is too small to satisfy the metabolic demand, the liver loses this peculiar ability, resulting in delayed synthetic dysfunction with poor bile production, coagulopathy, prolonged cholestasis and intractable ascites, which can lead to septic complications and high mortality. The term "small-for-size syndrome" (SFSS) was first[1] coined in liver transplantation as a consequence of size mismatch between graft and recipient, an event occurring especially in the setting of living donor liver transplantation (LDLT) or split liver transplantation[2], where the use of partial grafts has gained worldwide acceptance to overcome the shortage of cadaveric organs. However, the same concept can also be applied to the field of liver resection, where patients with marginally resectable tumors are at high risk of developing post-hepatectomy liver failure (PHLF)[3], a clinical manifestation comparable to the SFSS.

**DEFINITION**

There is not full consensus about the definition of SFSS. It was introduced in 1996 by Emond *et al*[1] and regarded the clinical manifestation following transplantation of small grafts in LDLT. The term SFSS on the basis of personal working experience, and no threshold values of liver function tests, was suggested. In 2005, Dahm *et al*[4] proposed a more precise definition. These authors described SFSS after liver transplantation as the presence of two of the following criteria recorded on three consecutive postoperative days: serum bilirubin > 100 µmol/l (6 mg/dl), international normalized ratio (INR) > 2 and presence of encephalopathy grade III or IV. The small-for-size syndrome usually occurs during the first postoperative week and is diagnosed after the exclusion of other causes such as technical complications (*e.g.* arterial or portal occlusion, outflow congestion, bile leak) and/or rejection or infections (*e.g.* cholangitis, sepsis).

The same concept is applicable to the field of hepatic surgery, where extended resections can lead to the development of PHLF. Many different definitions of PHLF have been proposed in the literature[5-7]. In trying to propose a more standardized definition, in 2011, Rahbari *et al*[7] suggested a simple and easily applicable definition of PHLF as a "postoperative acquired deterioration in the ability of the liver to maintain its synthetic, excretory and detoxifying functions, which are characterized by an increased INR and concomitant hyperbilirubinemia on or after postoperative day 5". They differentiated severity in three grades (A, B, C), according to whether changes in clinical management of the patient or invasive treatments are required. It is of interest that even if SFSS and PHLF can be viewed as the same manifestation of liver function impairment, the two terms and their relative definitions are currently separated. It would probably be of interest to join the two definitions into a single one, but at present no suggestions, regarding this topic, are present in the literature.

**PATHOPHYSIOLOGY**

The magnitude of the effect of increased portal flow after hepatectomy on the development of PHLF, though recognized, is currently not yet well established and most of the studies regarding this topic come from the transplantation experience.

High portal blood venous flow (PVF) has gained a central role in the pathogenesis of SFSS. Under normal physiological conditions, portal vein blood flow accounts for 75% of total hepatic inflow, or 90 mL/min per 100 g of liver tissue, while the hepatic artery contributes for 20%-25%[8]. The portal vein lacks intrinsic auto-regulation. Hence, after extended hepatectomy or transplantation of small grafts, the remnant liver is subjected to the portal flow destined to a whole liver, through a reduced micro-vascular bed[9]. Such a substantial increase of PVF and shear-stress on sinusoidal lining cells is inversely related to graft size. In > 75% partial hepatectomy, PVF increases by more than twice the baseline values, resulting in PHLF, with high morbidity and mortality[10].Although shear-stress is considered to be a necessary stimulus for hepatic regeneration[11], excessive forces can be detrimental to both the function and survival of the reduced-size organ: the result is damage of sinusoidal spaces with release of inflammatory cytokines, responsible for progressive hepatocyte necrosis[12]. Pathological findings include hepatocyte ballooning, tremendous mitochondrial swelling, irregular large gaps between sinusoidal lining cells, and collapse of the space of Disse[13].

Although portal vein pressure (PVP) is considered a reliable predictor of graft failure[14], the latter and PVF do not run parallel to each other; furthermore, the lack of correlation between graft weight/recipient body weight ratio (GRWR) and PVP has been investigated[15].

Blood flow regulation, which allows a steady rate of hepatic perfusion, depends not only on the classical arterial intrinsic regulation but also on an inverse relationship between portal and hepatic arterial flow, also known as hepatic arterial buffer response (HABR)[16]. When the portal blood flow increases, this leads to an elevated wash-out of adenosine levels in the space of Mall, contracting the hepatic artery[17]. Adenosine is unlikely to be the sole vascular regulator and other vaso-active compounds may contribute to HABR[18]. The consequences of such a diminished arterial blood flow manifest in the peripheral circulation as a centrilobular microvescicular steatosis or infarcts, or, in severely affected cases, as ischemic cholangitis in the hilum[19]. Hence, the clinical manifestations can range from mild cholestasis to liver failure. However, the optimal rate needed to sustain liver regeneration and function, without damage to the liver, is still not known and further experimental studies on animal models are needed.

**PREOPERATIVE PREDICTION**

Hepatectomy remains the first curative option for neoplasms of the liver. The mortality rate after major liver resections, *i.e.* the removal of three or more Coinaud segments, ranges from 3% to 7% in non-injured liver parenchyma and increases up to 32% in patients with cirrhosis[20]. Thus, the extent of parenchymal resection is an essential parameter in establishing both the operability of each patient and the risk of PHLF and this, to date, is still a subject of debate, probably due to different methods of measurement, variability in the segment volumetric distribution and degree of underlying disease.

The 3D volumetric CT reconstruction allows preoperative calculation of the liver volume, even of the single segments, and, more important, of the future liver remnant (FLR). With a normal function, FLR should range between 20% and 30% of total liver volume, whereas smaller volumes are correlated with increase of liver failure and infections[21,22]. Care must be taken when an underlying liver disease pre-exists. In "injured" livers, (steatosis, cholestasis, fibrosis, cirrhosis or chemotherapy) the FLR should be greater than 30%-40%[23]. Therefore, an accurate preoperative assessment of liver function is needed.

In patients with cirrhosis, the Child-Pugh score and the hepatic vein pressure gradient are the two most important restrictive criteria in selecting candidates for surgery[24,25] even if they do not provide precise assessment of liver resectability[26]. Metabolic tests based on the detoxifying properties of the liver have the advantage of providing a more reliable estimation of the hepatic function, and they are based on quantitative measures. Indocyanine green clearance is the most popular test[27], especially in Eastern countries, where it constitutes the pillar of preoperative algorithms for liver resection[28,29]. Other quantitative tests, such as the monoethylglycinexylidide[30] test, have led to good prediction of PHLF, but they have gained less popularity and are not routinely used. A simple and non-invasive method of measurement of liver stiffness (Fibroscan@) has recently been gaining broad consensus for predicting PHLF in selected patients[31], but further studies are needed to establish its potential role in patient selection for surgery.

Chemotherapy-induced liver injury is common in patients that received chemotherapy for colorectal liver metastases, and the two typical patterns are sinusoidal injury (sinusoidal obstruction syndrome) in oxaliplatin-based regimens, and steatohepatitis (CASH), associated with irinotecan treatment[32]. More than 6 cycles of oxaliplatin need a longer time interval before major hepatectomy, even though accountability for PHLF still remains a matter of debate[33], whereas irinotecan is associated with an increased risk of peri-operative mortality after hepatectomy[34]. Biopsy of the liver before surgery might be helpful to assess the grade of steatosis or the histological features of CASH, thus defining more precise windows between drug administration and surgery.

Cholestasis impairs liver regeneration, and levels of bilirubin above 2.9 mg/dl are related to a higher rate of liver failure after major hepatectomy[35]. Nevertheless, the use of preoperative biliary drainage is still controversial, except for acute cholangitis or small FLR that are candidates for portal vein embolization[36], in which case biliary drainage is highly recommended. Besides such patient-related factors, others, like age > 65 years, male sex and diabetes mellitus, are related to a high risk of PHLF[37]. Obesity is not per se a major predictor of liver failure[38].

In the setting of transplantation, liver volume assessment is represented by the GRWR or graft volume/standard liver volume ratio (GV/SLV): in LDLT safe thresholds are at least 0.8% of GRWR or 30%-40% of GV/SLV[2,39,40], with greater values in patients affected by portal hypertension or advanced chronic liver disease. There are reports on the successful use of smaller grafts[41], but in association with some intraoperative inflow modulations: a case report of a left lobe LDLT as low as 0.34% of GRWR underwent splenectomy and did not develop post-operative SFSS[42]. In liver transplantation, size is not always the sole factor responsible for graft post-transplant liver function[43], because graft quality is likewise important in order to avoid liver dysfunction or other complications. Aside from basic requirements for donor livers, the following donor factors have a negative impact on graft prognosis: age > 50 years, prolonged intensive care unit stay > 5 d, hypernatremia, prolonged cardiac/respiratory arrest and long ischemia times, administration of high dosage of vasopressors, severe systemic sepsis, steatosis > 30%, anatomic variations in vascular structure and, obviously, abnormal liver function, particularly with elevated serum bilirubin and gamma glutamyltransferase[44].

Prediction of SFSS and PHLF is feasible and is based on the calculation of liver volume up to the assessment of liver function. Evaluation of patient status can help to find the best candidate for surgery. In the field of liver transplantation, donor characteristics also have to be taken into account, defining which grafts are at higher risk of developing SFSS than others. A list of the above mentioned factors is shown in Table 1.

**ATTENUATING SFSS IN LIVER TRANSPLANTATION**

In the presence of high portal blood flow and/or small grafts (GRWR < 0.8%), several different technical flow manipulations can be performed to overcome graft hyperperfusion and reduce PVF, although there is no full consensus about their indications: portocaval shunt, mesocaval shunt, splenorenal shunt, splenectomy or ligation of the splenic artery. Boillot *et al*[45] reported the first successful mesocaval shunt with downstream ligation of the superior mesenteric vein in a left lobe transplantation (GRWR of 0.61%), based on previous experimental studies on pigs.

Hemi-portocaval shunt, *i.e.* anastomosis between the left or the right portal branch and the inferior vena cava in a permanent fashion, is advocated by Troisi *et al*[10] whenever the PVF at reperfusion exceeds three-four times the one recorded in the donor. None of the patients undergoing such a graft inflow modulation developed SFSS, with significant decrease of portal vein flow.

The effects of splenic flow diversion have been investigated in the presence of portal hypertension (PVP > 20 mmHg)[15] and/or of portal hyperperfusion (PVF > 250 ml/min per gram)[46]. However, when PVF exceeds 500 ml/min per gram, portosystemic shunt cannot be avoided.

Both splenic artery ligation (SAL) and splenectomy can be performed and are comparable in terms of outcome and overall survival[47], although for the latter, septic complications must always be taken into account. Splenectomy is considered superior to SAL for the purpose of increasing white balance and platelet count after LDLT, which is not achieved by SAL alone.

Splenic artery embolization represents a valid alternative to achieve portal decompression[48]. Furthermore, a linear correlation between PVF and graft-to-recipient spleen size ratio has been found, thus including the spleen size as a likely predictor of post-transplant portal hyperperfusion and SFSS[49].

Techniques of graft inflow modulation account for a certain risk of steal phenomenon[50]: portal vein thrombosis, encephalopathy, septic complications or hampered liver regeneration are described as principal side effects. It remains an open question whether and when portosystemic shunts should be removed[51], since hypoperfusion, as well as hyperperfusion, can also be detrimental for liver function.

According to the definition of Dahm *et al*[4], who stated that SFSS should be considered as a distinct entity, outflow obstruction per se should be excluded as a possible trigger, as it may reduce the hepatic function. However, one of the most discussed topics concerns the reconstruction of the middle hepatic vein (MHV) in right lobe grafts, since congestion of anterior segments (V-VIII) may lead to graft dysfunction[52]. A graft with inclusion of the MHV has been demonstrated to be technically and physiologically superior, but the use of this technique should be limited to selected cases in LDLT due to an increased risk for donor safety[53]. For MHV reconstruction, several transplant centers use various types of vascular grafts, with a predilection for large caliber autologous vessels (*i.e.* the superficial femoral vein), or also cryopreserved venous or arterial grafts[54].

**ATTENUATING PHLF IN EXTENDED HEPATECTOMY**

If the remnant liver volume is not sufficient to meet the future metabolic demand, a number of strategies can be adopted to increase the liver volume, preventing post-hepatectomy liver failure. Portal vein embolization (PVE) has become the most standardized procedure due to its safety and feasibility: it consists in the occlusion of portal flow ipsilateral to the lesion, inducing hypertrophy in the controlateral lobe. Makuuchi *et al*[55] first used this technique in 1982 to extend the limits of hepatic resection, thus increasing the number of cases suitable for curative surgery: in this early report, 14 patients underwent pre-operative PVE followed by major liver resection 6 to 41 d after embolization, with no occurrence of postoperative liver failure. After almost 30 years, the indications of PVE are still very poorly standardized: many authors indicate a residual liver volume less than 30% of total liver volume or up to 40% in injured livers as the critical threshold[56,57]. Surgery is usually performed 2 to 8 wk after PVE, with future liver remnant volume increased by 10% to 46%. From 70% to 100% of patients who underwent PVE, hemi-hepatectomy or extended hepatectomy could be performed. Following resection, the perioperative morbidity and mortality was less than 15% and 0%-7%, respectively[58-60].

Portal vein ligation (PVL) represents a good alternative, although there are no controlled studies clearly showing the superiority of PVE *vs* PVL. Portal vein ligation requires laparotomy and, furthermore, the volume gain is often limited due to formation of collaterals between the two different lobes[20]. PVL is not considered such a standardized and safe procedure as PVE, but patients who are candidates for 2-stage hepatectomy can benefit from this technique[61,62], recently adopted in a new surgical approach aimed at enhancing and accelerating the regeneration of the remnant liver[63]. In 2009, Schnitzbauer *et al*[63] reported on a case series of 25 marginally resectable patients with massive involvement of the right lobe by neoplastic nodules, on which an innovative 2-step technique was carried out. In the first step, right portal vein ligation and *in situ* splitting of the liver on the right side of the falciform ligament was performed; in the second step, after a median time interval of 9 d, extended hepatectomy (right trisectionectomy) was completed. The observed median increase in volume of the left lobe was 74%, but morbidity and mortality were significant (68% and 12%, respectively). Thereafter, the so-called advanced liver partition and PVL for staged hepatectomy, also known by the acronym ALPPS[69], has spread to many centers worldwide: the obtained median increase in volume ranges from 74% up to 87%, with surgery usually performed 5 to 30 d after the first step. However, mortality rates of 13% to 22% are still reported[64-67]. Although the procedure is innovative and attractive, these latter figures make it imperative to increase the number of patients treated with this strategy to better define its feasibility and limits[68].

In addition to the above, more studies are needed to understand the exact mechanisms of hepatic regeneration, also through biopsy of the remnant liver before and after hepatectomy, and measurements of portal flow and pressure should be provided. In fact, although the preserved functional capacity of the hypertrophied remnant liver could be established with functional tests (*e.g.* indocyanine green clearance) and through the uptake of 99mTc dimethyl iminodiacetic acid[69], excessive portal flow represents one of the main problems, determining a possible discrepancy between the relevant increase in volume and the amount of actually functioning parenchyma. De Santibanes *et al*[70], in 2012, claimed that the diseased right hemi-liver, left in place, acts as an auxiliary liver to assist the future liver remnant for the first and critical week after resection, but in true auxiliary transplantation, both the portal and arterial flows to two hemi-livers are maintained. Thus, contrary to auxiliary transplantation, in which the growth and functional recovery may progress harmonically with a real portal flow modulation, this phenomenon is not certain after extended hepatectomy with a small residual parenchyma. In other words, how can this "beneficial" re-direction of the entire portal flow to a "small-for-size" remnant liver comply with established principles of portal flow modulation in small-for-size transplantation? Research in animal models clearly shows that a portocaval shunt has a positive effect in attenuating liver injury after extensive hepatectomy, suggesting that a slower regeneration following reduction of portal flow may be more advisable than faster regeneration associated with temporary portal hyperflow[71,72]. In this view, more insights on the mechanisms and features of liver regeneration are needed to better understand the potential benefit of portal flow modulation to prevent postoperative liver failure[64].

**PHARMACOLOGICAL INTERVENTIONS**

Many drugs have been demonstrated to be effective in attenuating SFSS after living donor liver transplantation of small grafts, but most of them have been tested only in animal models[73,74], whereas clinical trials on human beings are still lacking. Furthermore, pharmacological portal flow modulation has been investigated: shear-stress attenuation has been achieved by somatostatin[75], through down-regulation of the endothelin-1 (sinusoidal vasoconstrictor) and up-regulation of heme-oxygenase-1 (vasodilatator and antioxidant). Nitric oxide pathway activation seems to be protective against ischemia-reperfusion injury both in liver resection and liver transplantation[76]. Therapeutic agents promoting liver regeneration, such as serotonin, are still a matter of debate for their controversial role[77]. Recently, autologous bone marrow stem cells have been used to increase liver regeneration prior to major liver resection. In particular, an enhanced parenchymal growth after portal vein embolization through the portal injection of CD133+ cells (in the non-embolized hepatic lobe) has been demonstrated, with a subsequent improvement of outcome after surgery[78]. Even though the specific effect of CD133+ cells is not completely understood[79], this approach is intriguing due to the possibility of combination with other techniques favoring post-transplant or post-hepatectomy liver function recovery, such as procedures of portal flow modulation.

**CONCLUSION**

Post-hepatectomy liver failure and small-for-size liver syndrome can be viewed as two sides of the same coin, since both of them can lead to an identical pattern of clinical manifestations, that is cholestasis, impairment of coagulation and development of ascites, and that can range up to irreversible organ non-function and death of the patient. Safe thresholds of remnant liver volume differ between liver transplantation and after extended hepatectomy, probably due to graft denervation, immunosuppressive therapy and severity of ischemia-reperfusion injury. However, preoperative assessment of liver function and size is crucial, while intraoperative recording of hemodynamic changes, before and after hepatectomy or liver transplantation, should be mandatory in order to perform inflow modulation, if necessary. Other strategies, which include pharmacological perioperative protection of the liver and stem cell injection, are being explored, but further studies are needed before they can be applied in the clinical field.

**REFERENCES**

1 **Emond JC**, Renz JF, Ferrell LD, Rosenthal P, Lim RC, Roberts JP, Lake JR,Ascher NL. Functional analysis of grafts from living donors. Implications for the treatment of older recipients. *Ann Surg* 1996; **224**: 544-552 [PMID: 8857858 DOI: 10.1097/2F00000658-199610000-00012]

2 **Kiuchi T**, Kasahara M, Uryuhara K, Inomata Y, Uemoto S, Asonuma K, Egawa H, Fujita S, Hayashi M, Tanaka K. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. *Transplantation* 1999; **67**: 321-327 [PMID: 10075602 DOI: 10.1097/2F00007890-199901270-00024]

3 **Jarnagin WR**, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. *Ann Surg* 2002; **236**: 397-406 [PMID: 12368667 DOI: 10.1097/2F00000658-200210000-00001]

4 **Dahm F**, Georgiev, P and Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. *Am J Transplant* 2005; **5**: 2605-2610 [PMID: 16212618 DOI: 10.1111/j.1600-6143.2005.01081.x]

5 **Balzan S**, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, Durand F. The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. *Ann Surg* 2005; **242**: 824-828 [PMID: 16327492 DOI: 10.1097/01.sla.0000189131.90876.9e]

6 **Mullen JT**, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, Abdalla EK, Curley SA, Capussotti L, Clary BM, Vauthey JN. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. *J Am Coll Surg* 2007; **204**: 854-862 [PMID: 17481498 DOI:10.1016/j.jamcollsurg.2006.12.032]

7 **Rahbari NN**, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, Makuuchi M, Dematteo RP, Christophi C, Banting S, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Yokoyama Y, Fan ST, Nimura Y, Figueras J, Capussotti L, Büchler MW, Weitz J. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). *Surgery* 2011; **149**: 713-724 [PMID: 21236455 DOI: 10.1016/j.surg.2010.10.001]

8 **Vollmar B**, Menger MD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. *Physiol Rev* 2009; **89**: 1269-1339 [PMID: 19789382 DOI: 10.1152/physrev.00027.2008]

9 **Glanemann M**, Eipel C, Nussler AK, Vollmar B, Neuhaus P. Hyperperfusion syndrome in small-for-size livers*. Eur Surg Res*; **37**: 335-341 [PMID: 16465057 DOI: 10.1159/000090333]

10 **Troisi R**, Ricciardi S, Smeets P, Petrovic M, Van Maele G, Colle I, Van Vlierberghe H, de Hemptinne B. Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver. *Am J Transplant* 2005; **5**: 1397-1404 [PMID: 15888047 DOI: 10.1111/j.1600-6143.2005.00850.x]

11 **Schoen JM**, Wang HH, Minuk GY, LauttWW. Shear stress-induced nitric oxide release triggers the liver regeneration cascade. *Nitric Oxide* 2001; **5**: 453-464 [PMID: 11587560 DOI: 10.1006/niox.2001.0373]

12 **Panis Y**, McMullan DM, Emond JC. Progressive necrosis after hepatectomy and the pathophysiology of liver failure after massive resection. *Surgery* 1997; **121**: 142-149 [PMID: 9037225 DOI: 10.1016/S0039-6060(97)90283-x]

13 **Man K**, Fan ST, Lo CM, Liu CL, Fung PC, Liang TB, Lee TK, Tsui SH, Ng IO, Zhang ZW, Wong J. Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. *Ann Surg* 2003; **237**:256-264 [PMID: 12560784 DOI: 10.1097/01.SLA.0000048976.11824.67]

14 **Sainz-Barriga M**, Scudeller L, Costa MG, de Hemptinne B, Troisi R. Lack of a correlation between portal vein flow and pressure: Toward a shared interpretation of hemodynamic stress governing inflow modulation in liver transplantation. *Liver Transpl* 2011; **17**: 836-848 [PMID: 21384528 DOI: 10.1002/lt.22295]

15 **Ito T**, Kiuchi T, Yamamoto H, Oike F, Ogura Y, Fujimoto Y, Hirohashi K, Tanaka AK. Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications. *Transplantation* 2003; **75**: 1313-1317 [PMID: 12717222]

16 **Smyrniotis V**, Kostopanagiotou G, Kondi A, Gamaletsos E, Theodoraki K, Kehagias D, Mystakidou K, Contis J. Hemodynamic interaction between portal vein and hepatic artery flow in small-for-size split liver transplantation. *Transpl Int* 2002; **15**: 355-360 [PMID: 12122512DOI: 10.1111/j.1432-2277.2002.tb00178.x]

17 **Eipel C**, Abshagen K, Vollmar B. Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. *World J Gastroenterol* 2010; **16**: 6046-57 [PMID: 21182219 DOI: 10.3748/wjg.v16.i48.6046]

18 **Mathie RT**, Alexander B. The role of adenosine in the hyperaemic response of the hepatic artery to portal vein occlusion (the 'buffer response'). *Br J Pharmacol* 1990; **100**: 626-630 [PMID: 1697200 DOI: 10.1111/2Fj.1476-5381.1990.tb15857.x]

19 **Demetris AJ**, Kelly DM, Eghtesad B, Fontes P, Wallis Marsh J, Tom K, Tan HP, Shaw-Stiffel T, Boig L, Novelli P, Planinsic R, Fung JJ, Marcos A. Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome. *Am J Surg Pathol* 2006; **30**: 986-993 [PMID: 16861970 DOI: 10.1097/00000478-200608000-00009]

20 **Broering DC**, Hillert C, Krupski G, Fischer L, Mueller L, Achilles EG, Schulte am Esch J, Rogiers X. Portal vein embolization vs. portal vein ligation for induction of hypertrophy of the future liver remnant. *J GastrointestSurg* 200; **6**: 905-913 [PMID: 12504230 DOI: 10.1016/S1091-255X(02)00122-1]

21 **Schindl MJ**, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ; Edinburgh Liver Surgery and Transplantation Experimental Research Group (eLISTER). The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection.*Gut* 2005; **54**: 289-296[PMID: 15647196 DOI: 10.1136/gut.2004.046524]

22 **Abdalla EK**, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. *Arch Surg* 2002; **137**: 675-680 [PMID: 12049538 DOI:10.1001/archsurg.137.6.675]

23 **Shoup M**, Gonen M, D'Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, Blumgart LH, Fong Y. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. *J Gastrointest Surg* 2003; **7**: 325-330 [PMID: 12654556 DOI: 10.1016/S1091-255X(02)00370-0]

24 **Bruix J**, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, Bru C, Rodés J. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. *Gastroenterology* 1996; **111**: 1018-1022 [PMID: 8831597 DOI: 10.1016/2FS0016-5085(96)70070-7]

25 **Forner A**, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. *Semin Liver Dis* 2010; **30**: 61-74 [PMID: 20175034 DOI: 10.1055/s-0030-1247133]

26 **Cucchetti A**, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, Grazi GL, Pinna AD Is portal hypertension a contraindication to hepatic resection? *Ann Surg* 2009; **250:** 922–928 [PMID: 19855258 DOI: 10.1097/SLA.0b013e3181b977a5]

27 **Scheingraber S**, Richter S, Igna D, Flesch S, Kopp B, Schilling MK. Indocyanine green disappearance rate is the most useful marker for liver resection. *Hepatogastroenterology* 2008; **55**: 1394-1399 [PMID: 18795697]

28 **Makuuchi M**, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S. Surgery for small liver cancers. *Semin Surg Oncol* 1993; **9**: 298-304 [PMID: 8210909 DOI: 10.1002/ssu.2980090404]

29 **Fan ST**. Liver functional reserve estimation: state of the art and relevance for local treatments: the Eastern perspective. *J Hepatobiliary Pancreat Sci* 2010; **17**: 380-384 [PMID: 19865790 DOI: 10.1007/s00534-009-0229-9]

30 **Ercolani G**, Grazi GL, Callivà R, Pierangeli F, Cescon M, Cavallari A, Mazziotti A. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. *Surgery* 2000; **127**: 464-471 [PMID: 10776439 DOI: 10.1067/msy.2000.104743]

31 **Cescon M**, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, Festi D, Pinna AD. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. *Ann Surg* 2012; **256**: 706-712 [PMID: 23095613 DOI: 10.1097/SLA.0b013e3182724ce8]

32 **Chun YS**, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. *Lancet Oncol* 2009; **10**: 278-286 [PMID: 19261256 doi: 10.1016/S1470-2045(09)70064-6]

33 **Nakano H**, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, Bachellier P, Jaeck D. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. *Ann Surg* 2008; **247**: 118-124 [PMID: 18156931 DOI: 10.1097/SLA.0b013e31815774de]

34 **Vauthey JN**, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. *J ClinOncol* 2006; **24**: 2065-2072 [PMID: 16648507 DOI: 10.1200/JCO.2005.05.3074]

35 **Farges O**, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, Mabrut JY, Adham M, Pruvot FR, Gigot JF. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. *Br J Surg* 2013; **100**: 274-283 [PMID: 23124720 DOI: 10.1002/bjs.8950]

36 **Iacono C**, Ruzzenente A, Campagnaro T, Bortolasi L, Valdegamberi A, Guglielmi A. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. *Ann Surg* 2013; **257**: 191-204. [PMID: 23013805 DOI: 10.1097/SLA.0b013e31826f4b0e]

37 **Hammond JS**, Guha IN, Beckingham IJ, Lobo DN. Prediction, prevention and management of postresection liver failure. *Br J Surg* 2011; **98**: 1188-1200 [PMID: 21725970 DOI: 10.1002/bjs.7630]

38 **Cucchetti A**, Cescon M, Ercolani G, Di Gioia P, Peri E, Pinna AD. Safety of hepatic resection in overweight and obese patients with cirrhosis.*Br J Surg* 2011; **98**:1147-1154 [PMID: 21509752 DOI: 10.1002/bjs.7516]

39 **Lo CM**, Fan ST, Liu CL, Chan JK, Lam BK, Lau GK, Wei WI, Wong J. Minimum graft size for successful living donor liver transplantation. *Transplantation* 1999; **68**:1112-1116 [PMID: 10551638]

40 **Kawasaki S**, Makuuchi M, Matsunami H, Hashikura Y, Ikegami T, Nakazawa Y, Chisuwa H, Terada M, Miyagawa S. Living related liver transplantation in adults. *Ann Surg* 1998; **227**: 269-274 [PMID: 9488526 DOI: 10.1097/2F00000658-199802000-00017]

41 **Masetti M**, Siniscalchi A, De Pietri L, Braglia V, Benedetto F, Di Cautero N, Begliomini B, Romano A, Miller CM, Ramacciato G, Pinna AD. Living donor liver transplantation with left liver graft. *Am J Transplant* 2004; **4**: 1713-1716 [PMID: 15367230 DOI: 10.1111/j.1600-6143.2004.00548.x]

42 **Lauro A**, Diago Uso T, Quintini C, Di Benedetto F, Dazzi A, De Ruvo N, Masetti M, Cautero N, Risaliti A, Zanfi C, Ramacciato G, Begliomini B, Siniscalchi A, Miller CM, Pinna AD. Adult-to-adult living donor liver transplantation using left lobes: the importance of surgical modulations on portal graft inflow. *Transplant Proc* 2007; **39**: 1874-6 [PMID: 17692638 DOI: 10.1016/j.transproceed.2007.05.052]

43 **Kiuchi T**, Onishi Y, Nakamura T. Small-for-size graft: not defined solely by being small for size. *Liver Transpl* 2010; **16**: 815-817 [PMID: 20583077 DOI: 10.1002/lt.22113]

44 **Tucker ON**, Heaton N. The 'small for size' liver syndrome. *Curr Opin Crit Care* 2005; **11**: 150-155 [PMID: 15758596 DOI: 10.1097/01.ccx.0000157080.11117.45]

45 **Boillot O**, Delafosse B, Méchet I, Boucaud C, Pouyet M. Small-for-size partial liver graft in an adult recipient; a new transplant technique. *Lancet* 2002; **359**: 406-407 [PMID: 11844516 DOI: 10.1016/S0140-6736(02)07593-1]

46 **Troisi R**, de Hemptinne B. Clinical relevance of adapting portal vein flow in living donor liver transplantation in adult patients. *Liver Transpl* 2003; **9**: S36-S41 [PMID: 12942477DOI: 10.1053/jlts.2003.50200]

47 **Yoshizumi T**, Taketomi A, Soejima Y, Ikegami T, Uchiyama H, Kayashima H, Harada N, Yamashita Y, Kawanaka H, Nishizak T, Maehara Y. The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. *Transpl Int* 2008; **21**: 833-842 [PMID: 18482177 DOI: 10.1111/j.1432-2277.2008.00678.x]

48 **Umeda Y**, Yagi T, Sadamori H, Matsukawa H, Matsuda H, Shinoura S, Iwamoto T, Satoh D, Iwagaki H, Tanaka N. Preoperative proximal splenic artery embolization: a safe and efficacious portal decompression technique that improves the outcome of live donor liver transplantation. *Transpl Int* 2007; **20**: 947-955 [PMID: 17617180 DOI: 10.1111/j.1432-2277.2007.00513.x]

49 **Cheng YF**, Huang TL, Chen TY, Concejero A, Tsang LL, Wang CC, Wang SH, Sun CK, Lin CC, Liu YW, Yang CH, Yong CC, Ou SY, Yu CY, Chiu KW, Jawan B, Eng HL, Chen CL. Liver graft-to-recipient spleen size ratio as a novel predictor of portal hyperperfusion syndrome in living donor liver transplantation. *Am J Transplant* 2006; **6**: 2994-2999 [PMID: 17061990 DOI: 10.1111/j.1600-6143.2006.01562.x]

50 **Oura T**, Taniguchi M, Shimamura T, Suzuki T, Yamashita K, Uno M, Goto R, Watanabe M, Kamiyama T, Matsushita M, Furukawa H, Todo S. Does the permanent portacaval shunt for a small-for-size graft in a living donor liver transplantation do more harm than good? *Am J Transplant* 2008; **8**: 250-252 [PMID: 18093277 DOI: 10.1111/j.1600-6143.2007.02045.x]

51 **Botha JF**, Campos BD, Johanning J, Mercer D, Grant W, Langnas A. Endovascular closure of a hemiportocaval shunt after small-for-size adult-to-adult left lobe living donor liver transplantation. *Liver Transpl* 2009; **15**: 1671-1675 [PMID: 19938118 DOI: 10.1002/lt.21944]

52 **Gyu Lee** S, Min Park K, Hwang S, Hun Kim K, Nak Choi D, Hyung Joo S, Soo Anh C, Won Nah Y, Yeong Jeon J, Hoon Park S, Suck Koh K, Hoon Han S, Taek Choi K, Sam Hwang K, Sugawara Y, Makuuchi M, Chul Min P. Modified right liver graft from a living donor to prevent congestion. *Transplantation* 2002; **74**: 54-59 [PMID: 12134099]

53 **Cattral MS**, Molinari M, Vollmer CM Jr, McGilvray I, Wei A, Walsh M, Adcock L, Marks N, Lilly L, Girgrah N, Levy G, Greig PD, Grant DR. Living-donor right hepatectomy with or without inclusion of middle hepatic vein: comparison of morbidity and outcome in 56 patients. *Am J Transplant* 2004; **4**: 751-757 [PMID: 15084170 DOI: 10.1111/j.1600-6143.2004.00405.x]

54 **Sugawara Y**, Makuuchi M, Sano K, Imamura H, Kaneko J, Ohkubo T, Matsui Y, Kokudo N. Vein reconstruction in modified right liver graft for living donor liver transplantation. *Ann Surg* 2003; **237**: 180-185 [PMID: 12560775 DOI: 10.1097/2F01.SLA.0000048444.40498.AD]

55 **Makuuchi M**, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunvén P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. *Surgery* 1990; **107**: 521-527 [PMID: 2333592]

56 **Capussotti L**, Muratore A, Baracchi F, Lelong B, Ferrero A, Regge D, Delpero JR. Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases. *Arch Surg* 2008; **143**: 978-982 [PMID: 18936377 DOI: 10.1001/archsurg.143.10.978]

57 **Aussilhou B**, Lesurtel M, Sauvanet A, Farges O, Dokmak S, Goasguen N, Sibert A, Vilgrain V, Belghiti J. Right portal vein ligation is as efficient as portal vein embolization to induce hypertrophy of the left liver remnant. *J Gastrointest Surg* 2008; **12**: 297-303 [PMID: 18060468 DOI: 10.1007/s11605-007-0410-x]

58 **Abulkhir A**, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, Habib N, Jiao LR. Preoperative portal vein embolization for major liver resection: a meta-analysis. *Ann Surg* 2008; **247**: 49-57 [PMID: 18156923 DOI: 10.1097/SLA.0b013e31815f6e5b]

59 **Liu H**, Zhu S. Present status and future perspectives of preoperative portal vein embolization. *Am J Surg* 2009; 197: 686-690 [PMID: 19249737 DOI: 10.1016/j.amjsurg.2008.04.022]

60 **Abdalla EK**, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. *Br J Surg* 2001; **88**: 165-175 [PMID: 11167863 DOI: 10.1046/j.1365-2168.2001.01658.x]

61 **Adam R**, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. *Ann Surg* 2000; **232**: 777-785 [PMID: 11088072 DOI: 10.1097/00000658-200012000-00006]

62 **Jaeck D**, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. *Ann Surg* 2004; **240**: 1037-1049 [PMID: 15570209 DOI: 10.1097/01.sla.0000145965.86383.89]

63 **Schnitzbauer AA**, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. *Ann Surg* 2012; **255**: 405-414 [PMID: 22330038 DOI: 10.1097/SLA.0b013e31824856f5]

64 **Alvarez FA**, Ardiles V, Sanchez Claria R, Pekolj J, de Santibañes E. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): tips and tricks. *J Gastrointest Surg* 2013; **17**: 814-821 [PMID: 23188224 DOI: 10.1007/s11605-012-2092-2]

65 **Knoefel WT**, Gabor I, Rehders A, Alexander A, Krausch M, Schulte am Esch J, Fürst G, Topp SA. In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection. *Br J Surg* 2013; **100**: 388-394 [PMID: 23124776 DOI: 10.1002/bjs.8955]

66 **Torres OJ**, Fernandes Ede S, Oliveira CV, Lima CX, Waechter FL, Moraes-Junior JM, Linhares MM, Pinto RD, Herman P, Machado MA. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): the Brazilian experience. *Arq Bras Cir Dig* 2013; **26**: 40-43 [PMID: 23702869 DOI: 10.1590/S0102-67202013000100009]

67 **Li J**, Girotti P, Königsrainer I, Ladurner R, Königsrainer A, Nadalin S. ALPPS in right trisectionectomy: a safe procedure to avoid postoperative liver failure? *J Gastrointest Surg* 2013; **17**: 956-961 [PMID: 23288719 DOI: 10.1007/s11605-012-2132-y]

68 **Shindoh J**, Vauthey JN, Zimmitti G, Curley SA, Huang SY, Mahvash A, Gupta S, Wallace MJ, Aloia TA. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. *J Am Coll Surg* 2013; **217**: 126-133 [PMID: 23632095 DOI: 10.1016/j.jamcollsurg.2013.03.004]

69 **de Santibañes E**, Alvarez FA, Ardiles V. How to avoid postoperative liver failure: a novel method. *World J Surg* 2012; **36**: 125-128. [PMID: 22045448 DOI: 10.1007/s00268-011-1331-0]

70 **de Santibañes E**, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: the "ALPPS" approach. *Ann Surg* 2012; **255**: 415-417. [PMID: 22330039 DOI: 10.1097/SLA.0b013e318248577d]

71 **Iida T**, Yagi S, Taniguchi K, Hori T, Uemoto S. Improvement of morphological changes after 70% hepatectomy with portocaval shunt: preclinical study in porcine model. *J Surg Res* 2007; **143**: 238-246 [PMID: 18023647 DOI 10.1016/j.jss.2006.11.020]

72 **Wang H**, Ohkohchi N, Enomoto Y, Usuda M, Miyagi S, Masuoka H, Sekiguchi S, Kawagishi N, Fujimori K, Sato A, Satomi S. Effect of portocaval shunt on residual extreme small liver after extended hepatectomy in porcine. *World J Surg* 2006; **30**: 2014-2022 [PMID: 16927066 DOI: 10.1007/s00268-005-0294-4]

73 **Yamanaka K**, Hatano E, Iguchi K, Yamamoto G, Sato M, Toriguchi K, Tanabe K, Takemoto K, Nakamura K, Koyama N, Narita M, Nagata H, Taura K, Uemoto S. Effect of olprinone on liver microstructure in rat partial liver transplantation. *J Surg Res* 2013; **183**: 391-396 [PMID: 23246009 DOI: 10.1016/j.jss.2012.11.033]

74 **Golse N**, Bucur PO, Adam R, Castaing D, Sa Cunha A, Vibert E. New paradigms in post-hepatectomy liver failure. *J Gastrointest Surg* 2001; **17**: 593-605 [PMID: 23161285 DOI: 10.1007/s11605-012-2048-6]

75 **Xu X**, Man K, Zheng SS, Liang TB, Lee TK, Ng KT, Fan ST, Lo CM. Attenuation of acute phase shear stress by somatostatin improves small-for-size liver graft survival. *Liver Transpl* 2006; **12**: 621-627 [PMID: 16555322 DOI: 10.1002/lt.20630]

76 **Siriussawakul A**, Zaky A, Lang JD. Role of nitric oxide in hepatic ischemia-reperfusion injury *World J Gastroenterol* 2010; **16**: 6079-6086 [PMID: 21182222 DOI: 10.3748/wjg.v16.i48.6079]

77 **Papadimas GK**, Tzirogiannis KN, Mykoniatis MG, Grypioti AD, Manta GA, Panoutsopoulos GI. The emerging role of serotonin in liver regeneration. *Swiss Med Wkly* 2012; **142**: w13548 [PMID: 22495635 DOI: 10.4414/smw.2012.13548]

78 **am Esch JS**, Schmelzle M, Fürst G, Robson SC, Krieg A, Duhme C, Tustas RY, Alexander A, Klein HM, Topp SA, Bode JG, Häussinger D, Eisenberger CF, Knoefel WT. Infusion of CD133+ bone marrow-derived stem cells after selective portal vein embolization enhances functional hepatic reserves after extended right hepatectomy: a retrospective single-center study. *Ann Surg* 2012; **255**: 79-85 [PMID: 22156926 DOI: 10.1097/SLA.0b013e31823d7d08]

79 **Fürst G**, Schulte am Esch J, Poll LW, Hosch SB, Fritz LB, Klein M, Godehardt E,Krieg A, Wecker B, Stoldt V, Stockschläder M, Eisenberger CF, Mödder U, Knoefel WT. Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. *Radiology* 2007; **243**: 171-179 [PMID: 17312278 DOI: 10.1148/radiol.2431060625]

**P-Reviewer** De Nardi P, Eghtesad B, Smith RC **S-Editor** Ma YJ **L-Editor** **E-Editor**

**Table 1 Predictive factors of small-for-size syndrome and post-hepatectomy liver failure**

|  |  |  |  |
| --- | --- | --- | --- |
| **Liver volume** | **Liver function** | **Patient-related**  | **Other** |
|  |  |  |  |
| FLR/TLV | CHILD-PUGH  | CALI | cholestasis  |
| GRWR or GV/SLV | HVPG | age > 65 yr[37] | liver stiffness[31] |
|  | ICG | male sex[37] | donor factors[44] |
|  | MEGX [30] | diabetes mellitus[37] |  |

FLR: future liver remnant; TLV: total liver volume; GRWR: graft weight-recipient body weight ratio; GV: graft volume; SLV: standard liver volume; HVPG: hepatic vein pressure gradient; ICG: indocyanine green clearance; MEGX: monoethylglycinexylidide; CALI: chemotherapy-induced liver injury.